#United States #New York #Pomerantz LLP #Theravance Biopharma #TBPH

Investigation into Theravance Biopharma, Inc.

On April 16, 2026, Pomerantz LLP, a prominent law firm specializing in corporate securities and antitrust class litigation, announced its investigation into claims concerning Theravance Biopharma, Inc. This scrutiny is fueled by allegations that the company, alongside certain officers and directors, may have engaged in unlawful business practices or securities fraud, which negatively affected its investors.

Background of Theravance Biopharma

Theravance Biopharma operates in the competitive biotechnology sector, focusing on developing innovative therapies. However, the company’s momentum took a significant hit due to disappointing results from its Phase 3 CYPRESS clinical trial. On March 3, 2026, Theravance released a critical statement noting that the study, which evaluated the efficacy and safety of ampreloxetine for treating symptomatic neurogenic orthostatic hypotension (nOH) stemming from multiple system atrophy (MSA), did not meet its primary endpoint measuring treatment efficacy.

The lackluster results forced Theravance to announce its decision to wind down its ampreloxetine program, triggering an immediate and severe response from investors. Following this disclosure, shares dropped dramatically—plummeting by $4.99, which equates to a 26.33% decline, closing at $13.96 per share the same day, thereby raising concerns of possible losses among shareholders.

Legal Implications and Pomerantz's Role

The ongoing investigation led by Pomerantz LLP centers on whether Theravance misrepresented the viability of its ampreloxetine therapy or withheld information that would have been crucial for investors. If any wrongdoing is substantiated, it could lead to significant ramifications for the company and its executives, and potentially result in substantial recoveries for affected shareholders.

Daniel Peyton, an attorney at Pomerantz, urged investors who believe they have been harmed to reach out for more information or to discuss the possibility of joining a class action lawsuit—highlighting the firm’s ongoing commitment to uphold the rights of investors adversely affected by corporate malpractice.

The Significance of This Case

Investigation results will not only impact the company’s future but will also serve as a crucial case study on transparency and ethics in the biotech industry. Securities fraud can result in severe penalties, both at the company and executive level, and is a reminder of the importance of fair disclosure to prevent investor losses.

With its roots tracing back over 85 years to the late Abraham L. Pomerantz, known as a pioneer in the field of class action litigation, Pomerantz has consistently fought for victims of securities fraud, ensuring they have recourse in the face of corporate misconduct.

If you are an investor impacted by this news, consider reaching out to Pomerantz LLP for further guidance. You can contact them at the given details for more personalized assistance regarding your investment rights and options moving forward.

This active investigation and the eventual findings will be closely watched by the biotech community and investors alike, highlighting the balance between innovation and corporate accountability.